Is a controlled trial of long-term oral anticoagulants in patients with stroke and non-rheumatic atrial fibrillation worthwhile?
A controlled randomised trial large enough to assess the value of anticoagulating stroke patients in atrial fibrillation would be difficult to conduct in the UK and the results would be applicable to only a small proportion of stroke patients. It would be more worthwhile to organise a trial that als...
Hoofdauteurs: | Sandercock, P, Warlow, C, Bamford, J, Peto, R, Starkey, I |
---|---|
Formaat: | Journal article |
Taal: | English |
Gepubliceerd in: |
1986
|
Gelijkaardige items
-
Rivaroxaban as an oral anticoagulant for stroke prevention in atrial fibrillation
door: Turpie AGG
Gepubliceerd in: (2014-03-01) -
A new era of anticoagulant therapy in the prevention of stroke in non-rheumatic atrial fibrillation
door: Andrei Viktorovich Fonyakin, et al.
Gepubliceerd in: (2012-09-01) -
Adherence to oral anticoagulation in ischemic stroke patients with atrial fibrillation
door: Paula Tiili, et al.
Gepubliceerd in: (2021-01-01) -
Old and new oral anticoagulants for secondary stroke prevention in atrial fibrillation
door: Tommaso Sacquegna, et al.
Gepubliceerd in: (2015-12-01) -
Prevalence of oral anticoagulation in atrial fibrillation
door: Eduardo Bartholomay, et al.
Gepubliceerd in: (2014-09-01)